TY  - GEN
AU  - Peintinger,F
AU  - Buzdar,A U
AU  - Kuerer,H M
AU  - Mejia,J A
AU  - Hatzis,C
AU  - Gonzalez-Angulo,A M
AU  - Pusztai,L
AU  - Esteva,F J
AU  - Dawood,S S
AU  - Green,M C
AU  - Hortobagyi,G N
AU  - Symmans,W F
TI  - Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
SN  - 1569-8041
PY  - 2009///0217
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Clinical Trials as Topic
KW  - Cyclophosphamide
KW  - Doxorubicin
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm, Residual
KW  - prevention & control
KW  - Neoplasms, Hormone-Dependent
KW  - Paclitaxel
KW  - Randomized Controlled Trials as Topic
KW  - Receptor, ErbB-2
KW  - biosynthesis
KW  - Receptors, Estrogen
KW  - metabolism
KW  - Receptors, Progesterone
KW  - Trastuzumab
N1  - Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.1093/annonc/mdn427
ER  -